Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03331250 · ClinicalTrials.gov registry record · Phase 2
Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
A Phase 2 study of Angiosarcoma and Epithelioid Hemangioendothelioma, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
- 2
- Study locations
NCT03331250 is a Phase 2 study of Angiosarcoma and Epithelioid Hemangioendothelioma that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 13 participants, below the 1,092-participant average among 6 other Angiosarcoma trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT03331250, a Phase 2 study of Angiosarcoma and Epithelioid Hemangioendothelioma, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is studying a drug as a possible treatment for Angiosarcoma or Epithelioid hemangioendothelioma (EHE). -The drug involved in this study is Eribulin
Conditions Studied
Interventions
- DRUG Eribulin
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2018-01-18 |
| Est. Completion | 2026-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03331250
The ClinicalTrials.gov registry entry for NCT03331250 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,092-participant average among 6 other Angiosarcoma trials with a reported enrollment target (99% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Angiosarcoma appearing as the primary indexed condition, and to 1 intervention - of which Eribulin is the first listed.
NCT03331250 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03331250 about?
NCT03331250 is a clinical study titled "Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)". This research study is studying a drug as a possible treatment for Angiosarcoma or Epithelioid hemangioendothelioma (EHE). -The drug involved in this study is Eribulin
What is the current status of trial NCT03331250?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2018-01-18. Estimated completion is 2026-02-01.
What conditions does trial NCT03331250 study?
This clinical trial studies the following conditions: Angiosarcoma, Epithelioid Hemangioendothelioma.
What interventions are being tested in trial NCT03331250?
The interventions under investigation include: Eribulin (DRUG).
Who is sponsoring clinical trial NCT03331250?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03331250 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Angiosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RECRUITING · Phase 2
-
Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma
RECRUITING · Phase 2
-
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
RECRUITING · Phase 1
-
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.